Biotech's reverse merger renaissance poised to continue
A biotech collected $820 million in investor commitments this month to take its China-sourced immunology drug onto the public markets. That would make it one of the largest, if not the ...
August 17, 2026 11:12 AM EDT Deals Biotech's reverse merger renaissance poised to continue Kyle LaHucik Biotech Correspondent A biotech collected $820 million in investor commitments this month to take its China-sourced immunology drug onto the public markets. That … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that